Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to ...

This fundamental study combines in vitro reconstitution experiments and molecular dynamics simulations to elucidate how membrane lipids are transported from the outer to the inner membrane of ...

Zipp integrates new AXS wheel sensor into 353 NSW and 303 SW, alongside wheel updates, a new hub system and Goodyear tyre ...

Microsoft Threat Intelligence observed the persistent growth and operational sophistication of Lumma Stealer, an ...

Gene editing, once a theoretical ambition, has matured into a revolutionary frontier in biotechnology. Technologies like CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs) have unlocked ...